NEW YORK (GenomeWeb) – The Geisinger Health System has struck a partnership with German personalized cancer services company Indivumed to collect and study patient samples and develop targeted treatments, the partners said today.

The agreement will enable Indivumed and Geisinger to collect samples from consenting patients who are already undergoing a surgical tumor resection. The partners will store portions of those tissue, blood, or urine samples at Geisinger via the MyCode repository, and in an Indivumed bank, where they will be analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.